Through this we will be able to efficiently differentiate and identify markers for therapeutic response between NSCLC‐ squamous and ‐adenocarcinoma; among Wnt‐, SHH‐, Group‐3‐ and Group‐4‐Medulloblastoma; and between TKI sensitive and TKI‐resistant CML cases. This evidence concerns the gene SHH and adenocarcinoma.